Hinova Pharma is a pharmaceutical company.
Hinova Pharma is an innovative drug research and development manufacturer that provides users with compound HC-1119 androgen receptor (AR) antagonism by using drug discovery systems such as medicinal chemistry, biological screening, process research, quality research, clinical reporting, and clinical research. Drugs, HC-1102 androgen receptor inhibitors and other products, for the treatment of advanced prostate cancer and breast cancer.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 6, 2020 | Series C | ¥1B | 1 | — | — | Detail |
Sep 1, 2020 | Series D | — | 1 | — | — | Detail |
Jul 31, 2019 | Series B | $40M | 3 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Sinopharm-CICC | — | Series C |
Innovitalize Capital | — | Series D |
Chengdu Dingjian New Material Partnership | — | Series B |
Silicon Valley Torch Fund | — | Series B |
Prosper Capital | — | Series B |